Form 4: Sight Sciences Director and 10% Owner Staffan Encrantz Increases Stake with Significant Share Purchases

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc., has significantly increased his direct beneficial ownership through multiple open market purchases of common stock totaling 128,189 shares over three days in late May 2025.

Summary

• Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc. (SGHT), acquired a total of 128,189 shares of common stock through open market purchases across three separate transactions.
• On May 27, 2025, Mr. Encrantz purchased 41,346 shares at a weighted average price of $3.436 per share, with prices ranging from $3.29 to $3.46.
• On May 28, 2025, an additional 26,715 shares were acquired at a weighted average price of $3.516 per share, with prices ranging from $3.325 to $3.60.
• The final reported transaction on May 29, 2025, involved the purchase of 60,128 shares at a weighted average price of $3.588 per share, with prices ranging from $3.50 to $3.71.
• Following these transactions, Mr. Encrantz's direct beneficial ownership stands at 1,157,705 shares, which includes 1,140,339 shares of common stock and 17,366 restricted stock units.
• Additionally, Mr. Encrantz has indirect beneficial ownership of 632,456 shares through the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, and 5,086,920 shares through Allegro Investment Fund, L.P., though he disclaims pecuniary interest in the latter and disclaims beneficial ownership in both except to the extent of his pecuniary interest in the Trust.

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant open market purchases by a key insider (Director and 10% owner), indicating strong confidence in the company's stock at current price levels. While disclaimers on indirect ownership exist, the direct purchases are a clear positive signal.

Positives

• A Director and 10% owner, Staffan Encrantz, has made significant open market purchases of Sight Sciences common stock, indicating confidence in the company's future prospects.
• The acquisition of 128,189 shares directly increases insider alignment with shareholder interests.
• The purchases were made at varying price points, suggesting a belief in value at current levels.

Negatives

• The transactions were not made pursuant to a Rule 10b5-1(c) plan, meaning they were not pre-scheduled and could be opportunistic.
• The reporting person disclaims beneficial ownership and pecuniary interest in a significant portion of the indirectly held shares (Allegro Investment Fund, L.P.), which, while standard for certain structures, means his direct financial exposure to those shares is limited.

Risks

• The reporting person disclaims beneficial ownership of 5,086,920 shares held by Allegro Investment Fund, L.P., and disclaims pecuniary interest in these shares, which could imply that his personal financial alignment with this large block of shares is limited despite his control over the investment manager.
• The purchases were not made under a Rule 10b5-1 plan, which means they were not pre-scheduled and could be perceived as opportunistic, though there is no indication of impropriety.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider's equity transactions and does not provide broader industry context or trends for the medical device or ophthalmology sector in which Sight Sciences operates.

Related Party Transactions

• The document discloses indirect beneficial ownership through the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust and Allegro Investment Fund, L.P., where the reporting person has a relationship (trustee, investment manager). While beneficial ownership is disclaimed for a significant portion, these represent dealings with entities related to the reporting person.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal, potentially increasing confidence in the company's stock.
• The increased direct ownership by a Director and 10% owner aligns his interests more closely with those of other shareholders.

Key Dates

Recommendation

Keywords

Sight Sciences, SGHT, Form 4, Insider Buying, Stock Purchase, Director, 10% Owner, Beneficial Ownership, Equity, SEC Filing